386 related articles for article (PubMed ID: 11124289)
1. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
Verin P; Easty DL; Secchi A; Ciprandi G; Partouche P; Nemeth-Wasmer G; Brancato R; Harrisberg CJ; Estivin-Ebrardt C; Coster DJ; Apel AJ; Coroneo MT; Knorr M; Carmichael TR; Kent-Smith BT; Abrantes P; Leonardi A; Cerqueti PM; Modorati G; Martinez M
Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
[TBL] [Abstract][Full Text] [Related]
3. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group.
Secchi A; Leonardi A; Discepola M; Deschenes J; Abelson MB
Acta Ophthalmol Scand Suppl; 2000; (230):48-51. PubMed ID: 11057351
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group.
Secchi A; Ciprandi G; Leonardi A; Deschenes J; Abelson MB
Acta Ophthalmol Scand Suppl; 2000; (230):42-7. PubMed ID: 11057350
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.
Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E
Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252
[TBL] [Abstract][Full Text] [Related]
7. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis.
Orfeo V; Vardaro A; Lena P; Mensitieri I; Tracey M; De Marco R
Eur J Ophthalmol; 2002; 12(4):262-6. PubMed ID: 12219994
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis.
Discepola M; Deschenes J; Abelson M
Acta Ophthalmol Scand Suppl; 1999; (228):43-6. PubMed ID: 10337432
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
Abelson MB; George MA; Schaefer K; Smith LM
J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.
D'Arienzo PA; Leonardi A; Bensch G
Clin Ther; 2002 Mar; 24(3):409-16. PubMed ID: 11952024
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.
Abelson MB; Kaplan AP
Clin Ther; 2002 Mar; 24(3):445-56. PubMed ID: 11952027
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
Abelson MB; Spitalny L
Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
[TBL] [Abstract][Full Text] [Related]
13. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
16. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test].
Allaire C; Siou-Mermet R; Bassols A
J Fr Ophtalmol; 2012 Sep; 35(7):491-8. PubMed ID: 22498504
[TBL] [Abstract][Full Text] [Related]
17. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
Abelson MB; Lanier RQ
Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
[TBL] [Abstract][Full Text] [Related]
18. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
Abelson MB; Welch DL
Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
